SEARCH

SEARCH BY CITATION

References

  • 1
    Blackburn WD. Management of osteoarthritis and rheumatoid arthritis: prospects and possibilities. Am J Med 1996; 100: 24S30S.
  • 2
    Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective 1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol 1998; 51(Suppl.): 816.
  • 3
    Thomas J, Straus WL, Bloom BS. Over-the-counter nonsteroidal anti-inflammatory drugs and risk of gastrointestinal symptoms. Am J Gastroenterol 2002; 97: 22159.
    Direct Link:
  • 4
    Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115: 78796.
  • 5
    Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword. Arthritis Rheum 1995; 38: 518.
  • 6
    Borda IT, Koff R. NSAIDs: A Profile of Adverse Effects. Philadelphia: Hanley and Belfus, Inc., 1995.
  • 7
    Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998; 104: 23S29S.
  • 8
    Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs. Lancet 1994; 343: 76972.
  • 9
    Goldstein JL, Correa P, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001; 96: 101927.
    Direct Link:
  • 10
    Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998; 41: 1591602.
  • 11
    Kivitz A, Eisen G, Zhao WW, et al. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract 2002; 51: 5307.
  • 12
    Goldstein JL, Kent JD, Zhao W, Recker D, Verburg KM. Reduced incidence of gastroduodenal ulcers with valdecoxib compared to ibuprofen and diclofenac in patients with rheumtoid arthrtits: a multicenter trial [Abstract]. Am J Gastroenterol 2001; 96(Suppl.): 9.
  • 13
    Goldstein JL, Talwalker S, Verburg KM, Recker D, Hubbard RC. Comparative gastroduodenal mucosal effects of valdecoxib, a potent COX-2 specific inhibitor, compared with naproxen and placebo [Abstract]. Gut 2001; 49(suppl. III): Abstract 2116.
  • 14
    Rordorf C, Kellett N, Mair S, et al. Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects. Aliment Pharmacol Ther 2003; 18: 53341.
  • 15
    Hunt RH, Harper S, Callegari P, et al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther 2003; 17: 20110.
  • 16
    Hawkey CJ, Laine L, Harper SE, et al. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Aliment Pharmacol Ther 2001; 15: 1593601.
  • 17
    Atherton C, Jones J, McKaig B, et al. Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: an integrated study. Clin Gastroenterol Hepatol 2004; 2: 11320.
  • 18
    Lanza FL, Rack MF, Simon TJ, et al. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther 1999; 13: 7617.
  • 19
    Baek SJ, Wilson LC, Lee CH, Eling TE. Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. J Pharmacol Exp Ther 2002; 301: 112631.
  • 20
    Turini ME, DuBois RN. Cyclooxygenase-2: a therapeutic target. Annu Rev Med 2002; 53: 3557.
  • 21
    Lipsky PE, Brooks P, Crofford LJ, et al. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Intern Med 2000; 160: 91320.
  • 22
    Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91: 1201317.
  • 23
    Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996; 271: 3315760.
  • 24
    Kargman S, Charleson S, Cartwright M, et al. Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 1996; 111: 44554.
  • 25
    Kuehl FA, Egan RW. Prostaglandins, arachidonic acid, and inflammation. Science 1980; 210: 97884.
  • 26
    Crofford LJ, Lipsky PE, Brooks P, et al. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 2000; 43: 413.
  • 27
    Born GVR, Cross MJ. The aggregation of blood platelets. J Physiol (Lond) 1963; 168: 17895.
  • 28
    Leese PT, Talwalker S, Kent JD, Recker DP. Valdecoxib does not impair platelet function. Am J Emerg Med 2002; 20: 27581.
  • 29
    Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 188899.
  • 30
    Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 2419.
  • 31
    MacDonald TM, Morant SV, Robinson GC, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997; 315: 13337.
  • 32
    Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 124755.
  • 33
    Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 15208.
  • 34
    Goldstein JL, Silverstein FE, Agrawal NM, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 168190.
    Direct Link:
  • 35
    Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 192933.
  • 36
    Harper S, Lee M, Curtis S, et al. A lower incidence of upper-GI perforations, ulcers and bleeds (PUBs) in patients treated with etoricoxib vs. nonselective cyclooxygenase inhibitors (NSAIDs). Arthritis & Rheumatism 2001; 44: S318. Abstract 1590.
  • 37
    Gierse JK, McDonald JJ, Hauser SD, et al. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem 1996; 271: 158104.
  • 38
    Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282: 19218.
  • 39
    Masferrer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994; 91: 322832.
  • 40
    Collantes E, Curtis SP, Lee KW, et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Fam Pract 2002; 3: 10.
  • 41
    Leung AT, Malmstrom K, Gallacher AE, et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 2002; 18: 4958.
  • 42
    Matsumoto AK, Melian A, Mandel DR, et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol. 2002; 29: 162330.
  • 43
    Makarowski W, Zhao W, Bevirt T, Recker D. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage. 2002; 10: 2906.
  • 44
    Bensen W, Weaver A, Espinoza L, et al. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. Rheumatology 2002; 41: 100816.
  • 45
    Bensen WG, Fiechtner JJ, McMillen JI, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999; 74: 1095105.
  • 46
    Leese PT, Recker DP, Kent JD. The COX-2 specific inhibitor valdecoxib does not impair platelet function in the elderly: results of a randomized controlled trial. J Clin Pharmacol 2002; 43: 50413.
  • 47
    Leese PT, Hubbard RC, Karim A, et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000; 40: 12432.
  • 48
    Greenberg HE, Gottesdiener K, Huntington M, et al. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharmacol 2000; 40: 150915.
  • 49
    Riendeau D, Percival MD, Brideau C, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001; 296: 55866.
  • 50
    Bensen WG, Zhao SZ, Burke TA, et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol 2000; 27: 187683.
  • 51
    Weaver J, Bonnel RA, Karwoski CB, Brinker AD, Beitz J. GI events leading to death in association with celecoxib and rofecoxib. Am J Gastroenterol 2001; 96: 344950.
  • 52
    Talley JJ, Brown DL, Carter JS, et al. 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem 2000; 43: 7757.
  • 53
    Daniels S, Talwalker S, Torri S, et al. Valdecoxib, a COX-2 specific inhibitor, is effective and well tolerated in treating women with primary dysmenorrhea. Obstet Gynecol 2002; 100: 3508.
  • 54
    Sikes DH, Agrawal NM, Zhao WW, et al. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol 2002; 14: 110111.
  • 55
    Goldstein JL, Eisen G, Stenson WF, et al. Significant reduction in serious upper gastrointestinal (UGI) events with celecoxib, a COX-2 specific inhibitor, compared with conventional NSAIDs: The SUCCESS-1 trial. Ann Rheum Dis 2001; 60(Suppl. 1): Abstract THU0182.
  • 56
    Gutthann SP, Garcia Rodriguez LA, Raiford DS. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997; 8: 1824.
  • 57
    Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 10758.